Dosni Roha Indonesia Valuation

Is ZBRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZBRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ZBRA (IDR78) is trading below our estimate of fair value (IDR4368.13)

Significantly Below Fair Value: ZBRA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZBRA?

Key metric: As ZBRA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ZBRA. This is calculated by dividing ZBRA's market cap by their current revenue.
What is ZBRA's PS Ratio?
PS Ratio	0.2x
Sales	Rp940.81b
Market Cap	Rp195.84b

ZBRA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	-13.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ZBRA's PS Ratio compare to its peers?

The above table shows the PS ratio for ZBRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.6x
MMIX Multi Medika Internasional	1.5x	n/a	Rp196.8b
SDPC Millennium Pharmacon International	0.06x	n/a	Rp220.4b
IRRA Itama Ranoraya	0.6x	n/a	Rp630.3b
PEVE PT. Penta Valent	0.2x	n/a	Rp430.8b
ZBRA Dosni Roha Indonesia	0.2x	n/a	Rp195.8b

Price-To-Sales vs Peers: ZBRA is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.6x).

Price to Sales Ratio vs Industry

How does ZBRA's PS Ratio compare vs other companies in the ID Healthcare Industry?

4 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	2.1x	11.3%
ZBRA Dosni Roha Indonesia	0.2x	n/a	US$12.34m
EPMT Enseval Putera Megatrading	0.2x	n/a	US$407.84m
PEVE PT. Penta Valent	0.2x	n/a	US$27.14m

4 Companies		Estimated Growth	Market Cap
Industry Avg.	2.1x	18.7%
ZBRA Dosni Roha Indonesia	0.2x	n/a	US$12.34m

No more companies

Price-To-Sales vs Industry: ZBRA is good value based on its Price-To-Sales Ratio (0.2x) compared to the ID Healthcare industry average (2.1x).

Price to Sales Ratio vs Fair Ratio

What is ZBRA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZBRA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ZBRA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.